why choose us

First received: August 16, 2023

Clinical Trial: Phase II Trial of Immunotherapeutic HPV Vaccine PRGN-2009 With Pembrolizumab Before Standard Treatment in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal Cancer

Study Status: Completed

Recruit Status: RECRUITING

Condition: Oropharyngeal Squamous Cell Carcinoma (SCC)

Study Type: INTERVENTIONAL


Official Title: Phase II Trial of Immunotherapeutic HPV Vaccine PRGN-2009 With Pembrolizumab Before Standard Treatment in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal Cancer

Brief Summary: Background:Cancers in and around the mouth associated with human papilloma virus (HPV) are common.Two treatments (the drug pembrolizumab and the HPV vaccine PRGN-2009) have been shown to work well when used individually against these cancers.Researchers want to find out if they might work better when used together.Objective:To test pembrolizumab combined with PRGN-2009 in people with HPV-positive cancers in and around the mouth.Eligibility:Adults aged 18 and older newly diagnosed with HPV-positive cancers in and…

Read more